



OPEN ACCESS

EDITED AND REVIEWED BY

John Varlotto,
Edwards Comprehensive Cancer Center,
United States

*CORRESPONDENCE

Michael C. Repka
✉ michael.repka@med.unc.edu

SPECIALTY SECTION

This article was submitted to
Radiation Oncology,
a section of the journal
Frontiers in Oncology

RECEIVED 23 March 2023

ACCEPTED 29 March 2023

PUBLISHED 05 April 2023

CITATION

Leu J, Akerman M, Mendez C, Lischalk JW,
Carpenter T, Ebling D, Haas JA, Witten M,
Barbaro M, Duic P, Tessler L and Repka MC
(2023) Corrigendum: Time interval from
diagnosis to treatment of brain metastases
with stereotactic radiosurgery is not
associated with radionecrosis or
local failure.
Front. Oncol. 13:1192726.
doi: 10.3389/fonc.2023.1192726

COPYRIGHT

© 2023 Leu, Akerman, Mendez, Lischalk,
Carpenter, Ebling, Haas, Witten, Barbaro,
Duic, Tessler and Repka. This is an open-
access article distributed under the terms of
the [Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Corrigendum: Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failure

Justin Leu¹, Meredith Akerman², Christopher Mendez³,
Jonathan W. Lischalk^{3,4}, Todd Carpenter³, David Ebling³,
Jonathan A. Haas^{3,4}, Matthew Witten⁵, Marissa Barbaro⁶,
Paul Duic⁶, Lee Tessler⁷ and Michael C. Repka^{8*}

¹Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, United States, ²Division of Health Services Research, New York University (NYU) Long Island School of Medicine, Mineola, NY, United States, ³Department of Radiation Oncology, Perlmutter Cancer Center at New York University (NYU) Long Island, Mineola, NY, United States, ⁴NYCyberKnife at Perlmutter Cancer Center – Manhattan, New York, NY, United States, ⁵Department of Medical Physics, Perlmutter Cancer Center at New York University (NYU) Long Island, Mineola, NY, United States, ⁶Department of Neurology, New York University (NYU) Long Island School of Medicine, Mineola, NY, United States, ⁷Department of Neurosurgery, Perlmutter Cancer Center at New York University (NYU) Long Island, Mineola, NY, United States, ⁸Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC, United States

KEYWORDS

stereotactic radiosurgery, brain metastases, immunotherapy, radionecrosis, treatment delays, cancer, radiation therapy, radiation necrosis

A corrigendum on

[Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failure](#)

by Leu J, Akerman M, Mendez C, Lischalk JW, Carpenter T, Ebling D, Haas JA, Witten M, Barbaro M, Duic P, Tessler L and Repka MC (2023). *Front. Oncol.* 13:1132777. doi: 10.3389/fonc.2023.1132777

Text Correction

In the published article, there was an error. One of the citations of Table 3 was incorrect and should have referred to Table 4 instead.

A correction has been made to **the Results section**, *Association between regional failure (distant brain failure) and other variables*, paragraph 1. This sentence previously stated:

“After univariate analyses, age at diagnosis, histology, MRI maximum axial dimension, time interval between diagnostic MRI and first treatment, time interval between CT simulation and first treatment, fractionated versus single fraction SRS, total dose, GTV, PTV, max GTV dose, presence of normal brain constraint, and a history of prior WBRT were not associated with regional failure (Table 3).”

The corrected sentence appears below:

“After univariate analyses, age at diagnosis, histology, MRI maximum axial dimension, time interval between diagnostic MRI and first treatment, time interval between CT simulation and first treatment, fractionated versus single fraction SRS, total dose, GTV, PTV, max GTV dose, presence of normal brain constraint, and a history of prior WBRT were not associated with regional failure (Table 4).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.